Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).

Kimura T, Katakura Y, Shimoda M, Kawasaki F, Yamabe M, Tatsumi F, Matsuki M, Iwamoto Y, Anno T, Fushimi Y, Kamei S, Kimura Y and 4 more

Show all authors

Nakanishi S, Mune T, Kaku K, Kaneto H

Diabetes, obesity & metabolism30 Aug 2023Cited by 22 (Europe PMC)

PMID37646192DOI10.1111/dom.15258PepBankPUB-37646192

Publisher page PubMedAsk about this study

Jump to 21 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study21

21 results from studies that gave the peptide. 21 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, HbA1c at 24 weeks was significantly lower with semaglutide than with dulaglutide.
In plain wordsIn Japanese adults with type 2 diabetes, semaglutide lowered HbA1c more than dulaglutide did after 24 weeks.
Peptide
Semaglutide
Outcome
DecreaseHbA1c at 24 weeks
Study
n = 107
Comparator
Dulaglutide
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
HbA1c
7.9%
semaglutide baseline
HbA1c
6.7%
semaglutide week 24
HbA1c
8.1%
dulaglutide baseline
HbA1c
7.4%
dulaglutide week 24
Source sentences
Summary
HbA1c level at 24 weeks was significantly lower in the semaglutide group (7.9 ± 0.5%-6.7 ± 0.5%) compared with the dulaglutide group (8.1 ± 0.6%-7.4 ± 0.8%) (p < .0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619201
02HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, HbA1c was higher with dulaglutide than semaglutide at 24 weeks.
In plain wordsIn Japanese patients with diabetes, blood sugar was higher with dulaglutide than semaglutide at 24 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c at 24 weeks
Study
n = 107
Comparator
Semaglutide
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
HbA1c
8.1%
Dulaglutide, baseline
HbA1c
7.4%
Dulaglutide, 24 weeks
HbA1c
7.9%
Semaglutide, baseline
HbA1c
6.7%
Semaglutide, 24 weeks
Source sentences
Summary
HbA1c level at 24 weeks was significantly lower in the semaglutide group (7.9 ± 0.5%-6.7 ± 0.5%) compared with the dulaglutide group (8.1 ± 0.6%-7.4 ± 0.8%) (p < .0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619213
03HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, semaglutide reduced body mass index more than dulaglutide.
In plain wordsIn Japanese adults with type 2 diabetes, semaglutide lowered body mass index more than dulaglutide did.
Peptide
Semaglutide
Outcome
DecreaseBody mass index reduction
Study
n = 107
Comparator
Dulaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Reduction in body mass index and visceral fat area were also more significant in the semaglutide group
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619202
04HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, semaglutide reduced visceral fat area more than dulaglutide.
In plain wordsIn Japanese adults with type 2 diabetes, semaglutide cut visceral fat more than dulaglutide did.
Peptide
Semaglutide
Outcome
DecreaseVisceral fat area reduction
Study
n = 107
Comparator
Dulaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Reduction in body mass index and visceral fat area were also more significant in the semaglutide group (p < .05, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619203
05HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, more patients reached HbA1c below 7% with semaglutide than with dulaglutide.
In plain wordsIn Japanese adults with type 2 diabetes, more people on semaglutide than on dulaglutide reached an HbA1c below 7%.
Peptide
Semaglutide
Outcome
IncreaseAchievement of HbA1c below 7%
Study
n = 107
Comparator
Dulaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The achievement rate of HbA1c <7% was higher in the semaglutide group (p < .0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619204
06HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, low-density lipoprotein cholesterol decreased in the semaglutide group.
In plain wordsIn Japanese adults with type 2 diabetes, LDL cholesterol went down in the semaglutide group.
Peptide
Semaglutide
Outcome
DecreaseLDL cholesterol
Study
n = 107
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
low-density lipoprotein cholesterol, alanine aminotransferase and γ-glutamyl transpeptidase were decreased in the semaglutide group
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619205
07HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, alanine aminotransferase decreased in the semaglutide group.
In plain wordsIn Japanese adults with type 2 diabetes, the liver enzyme ALT went down in the semaglutide group.
Peptide
Semaglutide
Outcome
DecreaseAlanine aminotransferase
Study
n = 107
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The parameters such as low-density lipoprotein cholesterol, alanine aminotransferase and γ-glutamyl transpeptidase were decreased in the semaglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619206
08HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, gamma-glutamyl transpeptidase decreased in the semaglutide group.
In plain wordsIn Japanese adults with type 2 diabetes, the liver enzyme GGT went down in the semaglutide group.
Peptide
Semaglutide
Outcome
DecreaseGamma-glutamyl transpeptidase
Study
n = 107
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The parameters such as low-density lipoprotein cholesterol, alanine aminotransferase and γ-glutamyl transpeptidase were decreased in the semaglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619207
09HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, only the semaglutide group, not the dulaglutide group, significantly improved the apolipoprotein B/A1 ratio.
In plain wordsIn Japanese adults with type 2 diabetes, only semaglutide, not dulaglutide, improved the ApoB/A1 ratio, a heart attack risk marker.
Peptide
Semaglutide
Outcome
DecreaseApolipoprotein B/A1 ratio
Study
n = 107
Comparator
Dulaglutide
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Surprisingly, only semaglutide group significantly improved the apolipoprotein B/A1 ratio, which is considered a useful myocardial infarction risk index.
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619208
10HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, the liver to spleen ratio on computed tomography rose significantly only in the semaglutide group, not the dulaglutide group.
In plain wordsIn Japanese adults with type 2 diabetes, scans showed a better liver to spleen ratio only with semaglutide, not dulaglutide.
Peptide
Semaglutide
Outcome
IncreaseLiver to spleen ratio on computed tomography
Study
n = 107
Comparator
Dulaglutide
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Using computed tomography, the liver to spleen ratio was significantly elevated only in the semaglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619209
11HumanRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes, gastrointestinal symptoms occurred more often with semaglutide (46.3%) than with dulaglutide (13.2%).
In plain wordsIn Japanese adults with type 2 diabetes, stomach and bowel symptoms were more common with semaglutide than with dulaglutide.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal symptoms
Study
n = 107
Comparator
Dulaglutide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
Gastrointestinal symptoms
46.3%
semaglutide
Gastrointestinal symptoms
13.2%
dulaglutide
Source sentences
Summary
In contrast, gastrointestinal symptoms were observed in 13.2% of dulaglutide and 46.3% of semaglutide group (p < .01).
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619210
12HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, the pain-related Diabetes Treatment-Related Quality of Life score was better with dulaglutide than with semaglutide.
In plain wordsIn Japanese adults with type 2 diabetes, treatment-related quality of life for pain was better with dulaglutide than with semaglutide.
Peptide
Semaglutide
Outcome
DecreaseDTR-QOL score for pain
Study
n = 107
Comparator
Dulaglutide
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The Diabetes Treatment-Related Quality of Life scores related to pain and gastrointestinal symptoms were also superior in the dulaglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619211
13HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, the gastrointestinal-symptom Diabetes Treatment-Related Quality of Life score was better with dulaglutide than with semaglutide.
In plain wordsIn Japanese adults with type 2 diabetes, treatment-related quality of life for stomach symptoms was better with dulaglutide than with semaglutide.
Peptide
Semaglutide
Outcome
DecreaseDTR-QOL score for gastrointestinal symptoms
Study
n = 107
Comparator
Dulaglutide
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The Diabetes Treatment-Related Quality of Life scores related to pain and gastrointestinal symptoms were also superior in the dulaglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619212
14HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, dulaglutide reduced BMI less than semaglutide.
In plain wordsIn Japanese patients with diabetes, dulaglutide reduced BMI less than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseBMI reduction
Study
n = 107
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Reduction in body mass index and visceral fat area were also more significant in the semaglutide group (p < .05, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619214
15HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, dulaglutide reduced visceral fat area less than semaglutide.
In plain wordsIn Japanese patients with diabetes, dulaglutide reduced internal abdominal fat less than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseVisceral fat area reduction
Study
n = 107
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Reduction in body mass index and visceral fat area were also more significant in the semaglutide group (p < .05, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619215
16HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, fewer dulaglutide recipients achieved HbA1c below 7% than semaglutide recipients.
In plain wordsIn Japanese patients with diabetes, fewer dulaglutide recipients achieved HbA1c below 7% than semaglutide recipients.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c below 7%
Study
n = 107
Comparator
Semaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The achievement rate of HbA1c <7% was higher in the semaglutide group (p < .0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619216
17HumanRandomized controlled trialSafety outcome
In Japanese patients with type 2 diabetes, gastrointestinal symptoms were less frequent with dulaglutide than semaglutide.
In plain wordsIn Japanese patients with diabetes, gastrointestinal symptoms were less frequent with dulaglutide than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseGastrointestinal symptoms
Study
n = 107
Comparator
Semaglutide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
Gastrointestinal symptoms
13.2%
Dulaglutide
Gastrointestinal symptoms
46.3%
Semaglutide
Source sentences
Summary
In contrast, gastrointestinal symptoms were observed in 13.2% of dulaglutide and 46.3% of semaglutide group (p < .01).
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619219
18HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, quality of life related to pain was better with dulaglutide than semaglutide.
In plain wordsIn Japanese patients with diabetes, quality of life related to pain was better with dulaglutide than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseQuality of life related to pain
Study
n = 107
Comparator
Semaglutide
Outcome group
Pain · Whole body
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The Diabetes Treatment-Related Quality of Life scores related to pain and gastrointestinal symptoms were also superior in the dulaglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619220
19HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, gastrointestinal symptom-related quality of life was better with dulaglutide than semaglutide.
In plain wordsIn Japanese patients with diabetes, quality of life related to digestive symptoms was better with dulaglutide than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseQuality of life related to gastrointestinal symptoms
Study
n = 107
Comparator
Semaglutide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The Diabetes Treatment-Related Quality of Life scores related to pain and gastrointestinal symptoms were also superior in the dulaglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619221
20HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, dulaglutide did not significantly improve the apolipoprotein B/A1 ratio, whereas semaglutide did.
In plain wordsIn Japanese patients with diabetes, dulaglutide did not significantly improve the blood fat ratio, whereas semaglutide did.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeApolipoprotein B/A1 ratio
Study
n = 53
Comparator
Baseline
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Surprisingly, only semaglutide group significantly improved the apolipoprotein B/A1 ratio, which is considered a useful myocardial infarction risk index.
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619217
21HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, dulaglutide did not significantly elevate the liver to spleen ratio, whereas semaglutide did.
In plain wordsIn Japanese patients with diabetes, dulaglutide did not significantly increase the liver to spleen ratio, whereas semaglutide did.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeLiver to spleen ratio
Study
n = 53
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Using computed tomography, the liver to spleen ratio was significantly elevated only in the semaglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial.
Report a problemFND-3764619218

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 9Current
28 Oct 2026, 02:03 UTC
The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).

Summary

Results from this study21

Version history

Subjects

Publication types

MeSH terms

Keywords